Stephen Gold, DO
Family Medicine · Lancaster, PANPI 1366402208
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 56.9% of the total. Among family medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,023 payments — averaging $38.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$44K
- AstraZeneca$6K
- Novo Nordisk$4K
- Pfizer$3K
- Lilly USA, LLC$2K
- GSK$1K
- plus $17K from 54 others
What the payments were for
- Consulting fees$7401%
- Speaking & faculty fees$36,20047%
- Travel & lodging$2,6663%
- Food & beverage$37,54048%
- Education$3660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$38,481
- FARXIGA$1,111
- Wegovy$492
- BREZTRI$375
- Auvelity$375
- Ozempic$373
- VOQUEZNA$359
- UBRELVY$354
- RYBELSUS$250
- Kerendia$250
- NURTEC ODT$248
- AIRSUPRA$245
- QULIPTA$244
- BREZTRI AEROSPHERE$225
- FLOWTRIEVER CATHETER, S$209
- CT THROMBECTOMY SYSTEM KIT$209
- Saxenda$125
- LINZESS$125
- Austedo XR$125
- EVENITY$125
How this compares
$77,512 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 237 | $275,033 |
| EliquisApixaban | 149 | $107,630 |
| OzempicSemaglutide | 73 | $78,834 |
| OxycontinOxycodone Hcl | 41 | $47,958 |
| WegovySemaglutide | 36 | $47,321 |
| VraylarCariprazine Hcl | 26 | $39,659 |
| JardianceEmpagliflozin | 42 | $39,490 |
| XareltoRivaroxaban | 26 | $34,658 |
| JanuviaSitagliptin Phosphate | 21 | $33,447 |
| Xtampza ErOxycodone Myristate | 15 | $28,724 |
| TrulicityDulaglutide | 19 | $25,121 |
| FarxigaDapagliflozin Propanediol | 33 | $24,143 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $17,661 |
| ProliaDenosumab | 11 | $16,389 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $15,689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,758 | $300,153256 claims |
| Novo NordiskOzempic, Wegovy | $4,159 | $126,155109 claims |
| PfizerEliquis | $2,617 | $107,630149 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix, Anoro Ellipta | $1,376 | $56,907130 claims |
| AbbVieVraylar, Qulipta, Synthroid | $44,139 | $55,27980 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $1,068 | $45,21553 claims |
| Johnson & JohnsonXarelto | $178 | $34,65826 claims |
| MerckJanuvia | $859 | $33,44721 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $82 | $28,72415 claims |
| AstraZenecaFarxiga, Symbicort | $5,539 | $27,23247 claims |
| AmgenProlia | $567 | $16,38911 claims |
| Astellas Pharma US IncMyrbetriq | $471 | $12,36411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Lancaster
- Michael SteelmanLancaster$29K
- Adam VoelckersLancaster$26K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.